The Indian state of Utter Pradesh reported the highest number of administered doses of the vaccine against the coronavirus (COVID-19) as of November 13, 2023. Furthermore, over 2.2 billion total vaccine doses were administered in India during the same time period.

Vaccination in India were administered since January 16, 2021, with the administration of vaccines to all health care workers in the first phase. In February, the vaccination program was expanded to cover front line workers. The second phase of the program began in March which included citizens above the age of 60 and subsequently, people above the age of 45 with comorbidities. India’s vaccination program currently includes two vaccines, namely, Oxford University – AstraZeneca’s Covidshield vaccine, manufactured by the Serum Institute of India and Bharat Biotech Covaxin. Russia's Sputnik V was expected to be added to the mix starting May 2021.

Out of the two billion COVID-19 vaccines administered, over 1.6 billion vaccines were Covishield vaccine developed by Oxford university and AstraZeneca as of September 1, 2022 in India. Vaccinations in India were administered since January 16, 2021, with the administration of vaccines to all health care workers in the first phase. In February, the vaccination program was expanded to cover front line workers. The second phase of the program began in March which included citizens above the age of 60 and subsequently, people above the age of 45 with comorbidities. India’s vaccination program currently includes three vaccines, namely, Oxford University – AstraZeneca’s Covishield vaccine, manufactured by the Serum Institute of India, Bharat Biotech Covaxin and Russia's Sputnik V.

The number of COVID-19 vaccination doses administered per 100 people in India rose to 156 as of Oct 27 2023. This dataset includes a chart with historical data for India Coronavirus Vaccination Rate.

Note: In these datasets, a person is defined as up to date if they have received at least one dose of an updated COVID-19 vaccine. The Centers for Disease Control and Prevention (CDC) recommends that certain groups, including adults ages 65 years and older, receive additional doses.

On 6/16/2023 CDPH replaced the booster measures with a new “Up to Date” measure based on CDC’s new recommendations, replacing the primary series, boosted, and bivalent booster metrics The definition of “primary series complete” has not changed and is based on previous recommendations that CDC has since simplified. A person cannot complete their primary series with a single dose of an updated vaccine. Whereas the booster measures were calculated using the eligible population as the denominator, the new up to date measure uses the total estimated population. Please note that the rates for some groups may change since the up to date measure is calculated differently than the previous booster and bivalent measures.

This data is from the same source as the Vaccine Progress Dashboard at https://covid19.ca.gov/vaccination-progress-data/ which summarizes vaccination data at the county level by county of residence. Where county of residence was not reported in a vaccination record, the county of provider that vaccinated the resident is included. This applies to less than 1% of vaccination records. The sum of county-level vaccinations does not equal statewide total vaccinations due to out-of-state residents vaccinated in California.

These data do not include doses administered by the following federal agencies who received vaccine allocated directly from CDC: Indian Health Service, Veterans Health Administration, Department of Defense, and the Federal Bureau of Prisons.

Totals for the Vaccine Progress Dashboard and this dataset may not match, as the Dashboard totals doses by Report Date and this dataset totals doses by Administration Date. Dose numbers may also change for a particular Administration Date as data is updated.

Previous updates:

• On March 3, 2023, with the release of HPI 3.0 in 2022, the previous equity scores have been updated to reflect more recent community survey information. This change represents an improvement to the way CDPH monitors health equity by using the latest and most accurate community data available. The HPI uses a collection of data sources and indicators to calculate a measure of community conditions ranging from the most to the least healthy based on economic, housing, and environmental measures.

• Starting on July 13, 2022, the denominator for calculating vaccine coverage has been changed from age 5+ to all ages to reflect new vaccine eligibility criteria. Previously the denominator was changed from age 16+ to age 12+ on May 18, 2021, then changed from age 12+ to age 5+ on November 10, 2021, to reflect previous changes in vaccine eligibility criteria. The previous datasets based on age 16+ and age 5+ denominators have been uploaded as archived tables.

• Starting on May 29, 2021 the methodology for calculating on-hand inventory in the shipped/delivered/on-hand dataset has changed. Please see the accompanying data dictionary for details. In addition, this dataset is now down to the ZIP code level.

India administered over 2.2 billion vaccine doses for the coronavirus (COVID-19) as of October 20, 2022. The number of people infected with the virus was declining across the Asian country. With the onset of the second wave since late March 2021, the central government increased funding to boost vaccination production.

According to a survey in India, around ** percent of people are not willing to take the COVID-19 vaccine due to fear of side effects of the vaccine. Among the respondents, approximately ** percent are are not willing to take the vaccine due to not being at risk of catching the virus.

Actual value and historical data chart for India Immunization Bcg Percent Of One Year Old Children

In 2023, the share of BCG vaccination coverage in India was ** percent. Meanwhile, the lowest share of BCG vaccination coverage was seen in 1981 with only **** percent. The figure reflects a clear increase immunization coverage trend with an increase in time.

Context

• First case of COVID-19 in India was announced on 27th January 2020 in Thrissur Kerala. After October 2020, there was some relief due to the subsiding of the curve of the covid case.
• In January 2020, the Government of India approved two vaccines i.e. Astra-Zeneca's Vaccine produced by Serum Institute - Covidsheild and Bharat Biotech's indigenous vaccine - Covaxin.
• This dataset deals with these vaccinations in India and provides insights into them. The two files provide information about daily COVID-19 vaccinations throughout the country and total vaccinations in each state.
• The data was collected from Our World in Data Github repo for covid-19 and Government of India website containing Vaccinations State Data, merged with relevant attributes, and uploaded.
• Government of India also approved Russia's Sputnik V for emergency use authorization on 12th April 2021.

Content

Covid-19_India_Daywise_Vaccinations.csv

Columns: - location- Location of the vaccination(country). - date- Date in format dd-mm-yyyy. - vaccine- Name of the vaccine(s) administered in the country on that day. - source_url- Source of the information for the vaccination. - total-vaccinations- Total number of doses administered till that day. If a person receives one dose of the vaccine, this metric goes up by 1. If they receive a second dose, it goes up by 1 again. - total_vaccinations_per_hundred- total_vaccinations per 100 people in the total population. - people_vaccinated- Total number of people who received at least one vaccine dose. If a person receives the first dose of a 2-dose vaccine, this metric goes up by 1. If they receive the second dose, the metric stays the same. - people_vaccinated_per_hundred- people_vaccinated per 100 people in the total population. - people_fully_vaccinated- Total number of people who received all doses prescribed by the vaccination protocol. If a person receives the first dose of a 2-dose vaccine, this metric stays the same. If they receive the second dose, the metric goes up by 1. - people_fully_vaccinated_per_hundred- people_fully_vaccinated per 100 people in the total population. - daily_vaccinations- New doses administered per day. - daily_vaccinations_per_million- daily_vaccinations per 1,000,000 people in the total population. - daily_change_in_vaccinations- Change in the number of doses administered (daily_vaccinations) from the previous day.

Covid-19_Statewise_Vaccination_India.csv

Columns: - State/Union Territory- Name of the State or Union Territory. - Population (2011 census)- Population of the State/UT based on 2011 census. - 1st dose- Number of first doses that were administered. - 2nd dose- Number of second doses that were administered. - Cumulative doses administered- Total number of doses administered till date. - Percentage of people given atleast one dose- Percent of the population of the state. - Percentage of people fully vaccinated- Percent of the population of the state.

Acknowledgements

I like to specify that I am only making available to Kagglers the data that is produced and maintained by Our World in Data through their Github repo, and also the Ministry of Health and Family Welfare Government of India which provide daily vaccine stats through their website. - Our World in Data Github Repo - Ministry of Health and Family Welfare Government of India

Inspiration

From this data, what you could do is: - Visualisations about the daily vaccination trends in the country. - Which state has the fastest pace in vaccination? - Prediction of future daily vaccinations in the country.

Approved COVID-19 Vaccines Market Outlook

The global market size for approved COVID-19 vaccines stood at approximately USD 45 billion in 2023 and is projected to reach around USD 78 billion by 2032, growing at a compound annual growth rate (CAGR) of 6.5% during the forecast period. This substantial growth is primarily driven by continuous advancements in vaccine technology, increasing global vaccination drives, and the emergence of new variants necessitating booster doses.

One of the primary growth factors for the approved COVID-19 vaccines market is the ongoing need for booster vaccinations. As new variants of the virus emerge, vaccine manufacturers are continuously enhancing existing vaccines to tackle these variants effectively. This continuous innovation ensures sustained demand for updated vaccines, thereby propelling market growth. Additionally, governments worldwide are investing heavily in vaccination programs to achieve herd immunity, further boosting market size. Initiatives like COVAX, which aim to provide equitable vaccine access, are also significant contributors to market expansion.

Another crucial factor driving market growth is the increased awareness and acceptance of vaccines among the global population. Intensive public health campaigns and educational movements have led to a higher acceptance rate of vaccines, reducing vaccine hesitancy. This trend is particularly significant in emerging economies where initial vaccine skepticism was high. The successful roll-out of initial vaccine doses has built public confidence, thereby increasing the uptake of booster doses and new vaccine variants.

The collaboration between pharmaceutical companies and governments has also played a pivotal role in the growth of the COVID-19 vaccines market. Strategic partnerships for vaccine production, distribution, and administration have streamlined the supply chain, making vaccines more accessible to the public. These collaborations have also facilitated bulk purchasing agreements, which have provided cost advantages and enhanced market penetration across various regions. Moreover, the establishment of new manufacturing facilities and the expansion of existing ones have significantly accelerated vaccine production capabilities.

The development of the COVID-19 RNA Vaccine has been a groundbreaking advancement in the fight against the pandemic. Unlike traditional vaccines, RNA vaccines work by introducing a small piece of genetic material from the virus into the body, prompting an immune response without using a live virus. This innovative approach has allowed for rapid development and deployment, significantly contributing to the global vaccination efforts. The flexibility of RNA technology also enables quick updates to the vaccine to address new variants, ensuring continued protection as the virus evolves. This adaptability has made RNA vaccines a crucial tool in achieving widespread immunity and controlling the spread of COVID-19.

Regionally, North America leads the market due to its advanced healthcare infrastructure and early adoption of vaccination programs. Europe follows closely, with significant contributions from countries like Germany, France, and the UK. The Asia Pacific region is witnessing rapid growth, driven by substantial investments in healthcare infrastructure and large-scale vaccination drives in countries like India and China. Meanwhile, Latin America and the Middle East & Africa are gradually catching up, supported by international aid and improving healthcare systems. The regional diversity ensures a balanced growth outlook for the global market.

Vaccine Type Analysis

The market for approved COVID-19 vaccines is segmented into various types, including mRNA vaccines, vector vaccines, protein subunit vaccines, inactivated vaccines, and others. mRNA vaccines, such as those developed by Pfizer-BioNTech and Moderna, have gained significant traction due to their high efficacy rates and the rapid speed of development. The flexibility of mRNA technology to adapt swiftly to new variants has positioned them as a frontrunner in the market. This segment is expected to continue its dominance, supported by ongoing research and development activities aimed at enhancing vaccine formulations and delivery mechanisms.

Vector vaccines, which use a modified virus to deliver genetic material into cells, represent another significant segment. AstraZeneca and Johnson & Johnson are key players in t

According to a survey conducted among MBBS (Bachelor of medicine and surgery) students in India, around ** percent of the respondents were aware that the MBBS students were eligible for COVID-19 vaccination in 2021. Among the respondents, approximately ** percent were aware about the number of vaccines available in the country.

This Dataset contains day-wise cumulative vaccination statistics of 1st and 2nd doses for the population of 15 to 18 years of age group and above 18 years of age for COVID-19 in India up to 10 June 2024

Context

"Experts have warned that the race to produce a Covid-19 vaccine could make the pandemic worse in the long run. A weak or partially effective candidate could potentially result in people believing they are immune to the virus, resulting in higher rates of infection. That warning was recently voiced by Professor Richard Peto of Oxford University and an adviser to the World Health Organization, who said that the first vaccine would be distributed all over the world, even if it had low efficacy."

" Around the world, some publics are extremely cautious about a vaccine and remain reluctant to take one, with the vast majority of respondents citing potential side effects as a reason to avoid getting one."

"So where are people least concerned about taking a Covid-19 vaccine if it was available? Ipsos MORI found that 97 percent of people in China would take one, along with 88 percent in Brazil, 87 percent in India and 85 percent in the UK. Russia recently announcing that it was aiming to bring its Sputnik V vaccine to the market at some stage this month, despite the fact that it did not undergo large scale testing. Only 54 percent of Russians say they would take a vaccine if it was available, with the share of people in France also low at 59 percent. In both Germany and the United States, 67 percent of respondents say they would agree to take a vaccine, according to the research." https://www.statista.com/chart/22768/share-who-agree-they-would-take-a-covid-19-vaccine/

Content

This chart shows the share who agree/disagree they would take a Covid-19 vaccine if it was available. Source: Ipsos MORI

Acknowledgements

Source: Ipsos MORI Niall McCarthy, Data Journalist. https://www.statista.com/chart/22768/share-who-agree-they-would-take-a-covid-19-vaccine/

Photo by Markus Winkler on Unsplash

Inspiration

Covid-19.

Snapshot img

Covid-19 Vaccination Market 2024-2028

The covid-19 vaccination market size is forecast to increase by USD -32.76 billion, at a CAGR of -37.4% between 2023 and 2028. The market is experiencing significant growth due to the expansion of vaccination programs worldwide. Governments and international organizations are investing heavily in vaccination initiatives to contain the spread of the virus. The rising research and development (R&D) investment in the development of Covid-19 vaccines is another major growth factor. However, the high cost of production of Covid-19 vaccines poses a significant challenge to market growth. Manufacturers are exploring various strategies to reduce production costs while maintaining vaccine efficacy and safety. The market is expected to witness strong growth in the coming years as more effective and affordable vaccines become available. poiuyfrtyh

What will the Covid-19 Vaccination Market Size be During the Forecast Period?

Download Report Sample to Unlock the Covid-19 Vaccination Market Size for the Forecast Period and Other Important Statistics

Market Dynamics

The COVID-19 pandemic has brought about an unprecedented global health crisis, leading to the development of numerous vaccines to mitigate its impact. This content focuses on various aspects of COVID-19 vaccines, including production, distribution, administration, efficacy, safety, and regulations. COVID-19 vaccine production has been a top priority for researchers and pharmaceutical companies worldwide. Several manufacturers have developed vaccines using various technologies such as mRNA, viral vector, and protein subunit, undergoing rigorous testing and clinical trials to ensure safety and efficacy. Once vaccines receive approval from regulatory bodies, they are distributed to healthcare facilities and vaccination centers, requiring careful planning and coordination. Governments and international organizations are working to ensure equitable distribution, prioritizing vulnerable populations and herd immunity. Vaccine administration involves healthcare professionals delivering vaccines through injections, with proper training and safety protocols to minimize adverse reactions. Efficacy refers to the vaccine's ability to prevent infection or reduce the severity of symptoms, with most vaccines showing high efficacy rates, ranging from 60% to 95%. Vaccine safety is monitored closely, and while common side effects include pain and swelling at the injection site, fever, and fatigue, serious side effects are rare.

Vaccine procurement involves purchasing vaccines from manufacturers, with governments securing supplies through contracts and partnerships. Vaccine allocation ensures that vaccines are distributed to specific populations, with priority given to vulnerable groups like healthcare workers and the elderly. Vaccine prioritization determines which populations should receive vaccines first, based on risk factors. Vaccine passports are digital or physical documents that prove vaccination status, and may be required for travel or work, with regulations varying by jurisdiction. Vaccine mandates, which require vaccination for employment or participation in certain activities, remain a controversial issue. Vaccine regulations ensure vaccines are safe and effective, and policies governing vaccine use in schools, workplaces, and travel may change as supplies and public health conditions evolve.

Covid-19 Vaccination Market Driver

The expansion of vaccination programs is the key driver of the market. The market is experiencing significant growth due to the increasing demand for vaccines as governments and healthcare organizations prioritize widespread vaccination to control the virus and achieve herd immunity. This heightened demand leads to increased production and sales for vaccine manufacturers, resulting in long-term procurement contracts being signed to ensure a consistent vaccine supply. These contracts provide stability and revenue for manufacturers, with more contracts expected to be established as vaccination programs expand.

Vaccine distribution, administration, and logistics are crucial elements in the vaccine market, requiring efficient vaccine storage, transportation, and scheduling. Vaccine safety, efficacy, and monitoring are also vital considerations, along with addressing vaccine hesitancy and acceptance through education and outreach efforts. Vaccine regulations, policies, and campaigns are essential in ensuring vaccine coverage, immunity, and compliance with side effects and potential mandates or certificates.

Covid-19 Vaccination Market Trends

Rising research and development investment is the upcoming trend in the market. The Covid-19 pandemic has necessitated the rapid development, production, and distribution of vaccines to prevent and treat the disease caused by the SARS-CoV-2 virus. Governments and the private sector have collaborated to invest in vacc

Actual value and historical data chart for India Immunization Dpt Percent Of Children Ages 12 23 Months

In 2023, the share of DTP1 vaccination coverage in India was ** percent. Meanwhile, the lowest share of vaccination coverage was seen in 1980 with ** percent. The figure reflects a clear increase in the immunization coverage trend with an increase in time.

Actual value and historical data chart for India Immunization Hepb3 Percent Of One Year Old Children

BackgroundTo assess the effect of health information on immunisation uptake in rural India, we conducted an individually randomised controlled trial of health information messages targeting the mothers of unvaccinated or incompletely vaccinated children through home visits in rural Uttar Pradesh, India.Methods and findingsThe study tested a brief intervention that provided mothers face-to-face with information on the benefits of the tetanus vaccine. Participants were 722 mothers of children aged 0–36 months who had not received 3 doses of diphtheria–pertussis–tetanus (DPT) vaccine (DPT3). Mothers were randomly assigned in a ratio of 1:1:1 to 1 of 3 study arms: mothers in the first treatment group received information framed as a gain (e.g., the child is less likely to get tetanus and more likely to be healthy if vaccinated), mothers in the second treatment group received information framed in terms of a loss (e.g., the child is more likely to get tetanus and suffer ill health if not vaccinated), and the third arm acted as a control group, with no information given to the mother. Surveys were conducted at baseline (September 2015) and after the intervention (April 2016). The primary outcome was the proportion of children who had received DPT3 measured after 7 months of follow-up. The analysis was by intention to treat. A total of 16 (2.2%) participants were lost to follow-up. The coverage of DPT3 was 28% in the control group and 43% in the pooled information groups, giving a risk difference of 15 percentage points (95% CI: 7% to 22%, p

As at January 2021, Bangladesh had received *********** doses of the AstraZeneca vaccine produced by the Serum Institute of India. India is one of the biggest producers of the vaccine worldwide. On January 20, the government of India launched its "Vaccine Maitri" (Vaccine Friendship) initiative to support its neighboring countries as well as countries with a significant number of Indian citizens.

Actual value and historical data chart for India Immunization Hib3 Percent Of Children Ages 12 23 Months